Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05485155 · ClinicalTrials.gov registry record · Phase 2
Zemaira Eosinophilic Esophagitis Pilot Study
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT05485155 is a Phase 2 study of Eosinophilic Esophagitis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 15 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05485155, a Phase 2 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Conditions Studied
Interventions
- DRUG Alpha-proteinase inhibitor
Study Locations (2)
Maryland
- The National Institutes of Health - Bethesda
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05485155
The ClinicalTrials.gov registry entry for NCT05485155 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Alpha-proteinase inhibitor is the first listed.
NCT05485155 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT05485155 about?
NCT05485155 is a clinical study titled "Zemaira Eosinophilic Esophagitis Pilot Study". This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
What is the current status of trial NCT05485155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-05-15. Estimated completion is 2027-01.
What conditions does trial NCT05485155 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT05485155?
The interventions under investigation include: Alpha-proteinase inhibitor (DRUG).
Who is sponsoring clinical trial NCT05485155?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05485155 being conducted?
This trial has 2 study locations across Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.